recommendation, the Commission considers a significant adverse comment to be one where the commenter explains why revising the list of regulated phthalates would be inappropriate. We note that comments on either the underlying determinations or phthalates final rules are not considered significant adverse comments because the only change this rule makes is to revise the list of covered phthalates.

Should the Commission receive significant adverse comment, the Commission would withdraw this direct final rule. Depending on the comments and other circumstances, the Commission may then incorporate the adverse comment into a subsequent direct final rule or publish a notice of proposed rulemaking, providing an opportunity for public comment.

D. Regulatory Flexibility Act

The Regulatory Flexibility Act (RFA) generally requires that agencies review proposed and final rules for their potential economic impact on small entities, including small businesses, and prepare regulatory flexibility analyses. 5 U.S.C. 603 and 604. CPSC conducted a final regulatory flexibility analysis (FRFA) for the determinations rule that the Commission issued in August 2017. The FRFA found that “the impact of the determinations on small businesses would be to reduce the burden of third party testing for phthalate content and would be expected to be entirely beneficial.” 82 FR 41171. As explained above, this direct final rule takes the limited action of revising the list of covered phthalates to bring the determinations rule into line with the phthalates rule so that companies will be able to use the determinations to reduce third party testing under the phthalates rule as they have under the statutory prohibitions.

E. Effective Date

As discussed in section C of this preamble, this is a direct final rule. Unless we receive a significant adverse comment within 30 days, the rule will take effect on April 25, 2018.

List of Subjects in 16 CFR Part 1308

Business and industry, Consumer protection, Imports, Infants and children, Product testing and certification, Toys.

Accordingly, the Commission amends 16 CFR part 1308 as follows:

PART 1308—PROHIBITION OF CHILDREN’S TOYS AND CHILD CARE ARTICLES CONTAINING SPECIFIED PHYTHALATES; DETERMINATIONS REGARDING CERTAIN PLASTICS

1. The authority citation for part 1308 continues to read as follows:


2. Revise § 1308.1 to read as follows:

§ 1308.1 Prohibited children’s toys and child care articles containing specified phthalates and testing requirements.

Section 108(a) of the Consumer Product Safety Improvement Act of 2008 (CPSIA) permanently prohibits any children’s toy or child care article that contains concentrations of more than 0.1 percent of di-(2-ethylhexyl) phthalate (DEHP), dibutyl phthalate (DBP), or benzyl butyl phthalate (BBP). In accordance with section 108(b)(3) of the CPSIA, 16 CFR part 1307 prohibits any children’s toy or child care article that contains concentrations of more than 0.1 percent of diisononyl phthalate (DINP), di(2-ethylhexyl) phthalate (DEHP), di-isononyl phthalate (DINP), di-n-nonyl phthalate (DHNAP), or di-2-ethylhexyl phthalate (DEHP) is prohibited. Materials used in children’s toys and child care articles subject to section 108(a) of the CPSIA and 16 CFR part 1307 must comply with the third party testing requirements of section 14(a)(2) of the Consumer Product Safety Act (CPSA), unless listed in § 1308.2.

Alberta E. Mills, Acting Secretary, U.S. Consumer Product Safety Commission.

[FR Doc. 2018–01451 Filed 1–25–18; 8:45 am]

BILLING CODE 6355–01–P

DEPARTMENT OF LABOR

Veterans’ Employment and Training Service

20 CFR Part 1011

RIN 1293–AA21

Honoring Investments in Recruiting and Employing American Military Veterans (HIRE Vets) Medallion Program; Agency Information Collection Activities; OMB Approvals

AGENCY: Veterans’ Employment and Training Service, Labor.

ACTION: OMB approval of information collections under Paperwork Reduction Act.

SUMMARY: This document announces that the Office of Management and Budget (OMB) has approved the information collections associated with the Honoring Investments in Recruiting and Employing American Military Veterans (HIRE Vets) Medallion Program rule under the Paperwork Reduction Act of 1995 (PRA).

DATES: On January 9, 2018, OMB approved the information collection request (ICR) the Veterans’ Employment and Training Service (VETS) submitted to implement the HIRE Vets Medallion Program Rule published on November 13, 2017 (82 FR 52186) and an associated program demonstration for 2018. Employers seeking recognition under the HIRE Vets Medallion Program Demonstration may submit applications once the Program Demonstration begins on or about January 31, 2018.

ADDRESSES: A copy of this ICR with applicable supporting documentation, including a description of the likely respondents, proposed frequency of response, and estimated total burden, may be obtained free of charge by contacting Randall Smith, Veterans’ Employment and Training Service, U.S. Department of Labor, Room S–1325, 200 Constitution Avenue NW, Washington, DC 20210, email: HIREVETS@dol.gov, telephone: (202) 693–4700 or TTY (877) 889–5627 (these are not toll-free numbers).

FOR FURTHER INFORMATION CONTACT: Randall Smith, Veterans’ Employment and Training Service, U.S. Department of Labor, Room S–1325, 200 Constitution Avenue NW, Washington, DC 20210, email: HIREVETS@dol.gov, telephone: (202) 693–4700 or TTY (877) 889–5627 (these are not toll-free numbers).

SUPPLEMENTARY INFORMATION: The PRA, 44 U.S.C. 3501 et seq., and its attendant regulations, 5 CFR part 1320, require a Federal agency to consider the impact of paperwork and other information collection burdens imposed on the public and to solicit public comments on the information collections. The PRA also provides that an agency may not collect or sponsor the collection of information unless it displays a currently valid OMB control number. See 5 CFR 1320.8(b)(3)(vi). OMB has approved the HIRE Vets Medallion Program information collections under control number 1293–0015.

In accordance with the PRA, VETS solicited comments on the HIRE Vets Medallion Program information collections as they were proposed in a Notice of Proposed Rulemaking published August 18, 2017 (82 FR 39371). See 44 U.S.C. 3506(c)(2). The Department also submitted a
contemporaneous request for OMB review of the proposed HIRE Vets Medallion Program information collections, in accordance with 44 U.S.C. 3507(d). On October 25, 2017, OMB issued a notice of action instructing the Department of Labor (DOL) to resubmit the information collections after taking public comments on the NPRM into consideration. See OMB ICR Reference Number 201707–1293–001. VETS published the HIRE Vets Medallion Program Final Rule in the Federal Register on November 13, 2017 (82 FR 52186). On the same day, DOL submitted the ICR that OMB requested, and OMB approved the ICR on January 9, 2018. See OMB ICR Reference Number 201710–1293–002.

For additional substantive information about this ICR, see the related documents published in the Federal Register on August 18, 2017 (82 FR 39371), and November 13, 2017 (82 FR 52186).

The information collection and its annual burden on the public may be summarized as follows:

**Agency:** DOL–VETS.

**Title of Collection:** Honoring Investments in Recruiting and Employing (HIRE) American Military Veterans (HIRE Vets) Medallion Program.

**OMB Control Number:** 1293–0015.

**Affected Public:** Private Sector—businesses or other for-profits.

**Total Estimated Number of Annual Responses:** 34,184.

**Total Estimated Annual Time Burden:** 58,556 hours.

**Total Estimated Annual Other Costs Burden:** $1,045,486.

**Authority:** 44 U.S.C. 3507(a)(1)(D).

**OMB Control Number:** 1293–0015.

**Authority:** 44 U.S.C. 3506(c).

Dated: January 18, 2018.

J.S. Shellenberger,
Deputy Assistant Secretary for the Veterans’ Employment and Training Service.

[FR Doc. 2016–01262 Filed 1–25–18; 8:45 am]

**BILLING CODE 4510–79–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**21 CFR Part 600**

[Docket No. FDA–2017–N–7007]

**RIN 0910–AH49**

**Removal of Certain Time of Inspection and Duties of Inspector Regulations for Biological Products**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Direct final rule.

**SUMMARY:** The Food and Drug Administration (FDA, Agency, or we) is amending the general biologics regulations relating to time of inspection requirements and also removing duties of inspector requirements. FDA is taking this action to remove outdated requirements and accommodate new approaches, such as a risk-based inspection frequency for drug establishments, thereby providing flexibility without diminishing public health protections. This action is part of FDA’s implementation of Executive Orders (E.O.s) 13771 and 13777. Under these E.O.s, FDA is comprehensively reviewing existing regulations to identify opportunities for repeal, replacement, or modification that will result in meaningful burden reduction while allowing the Agency to achieve our public health mission and fulfill statutory obligations. The Agency is issuing these amendments directly as a final rule because we believe they are noncontroversial and FDA anticipates no significant adverse comments.

**DATES:** This rule is effective June 11, 2018. Submit either electronic or written comments on the direct final rule or its companion proposed rule by April 11, 2018. If FDA receives no significant adverse comments within the specified comment period, the Agency intends to publish a document confirming the effective date of the final rule in the Federal Register within 30 days after the comment period on this direct final rule ends. If timely significant adverse comments are received, the Agency will publish a document in the Federal Register withdrawing this direct final rule within 30 days after the comment period on this direct final rule ends.

**ADDRESSES:** You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before April 11, 2018. The https://www.regulations.gov electronic filing system will accept comments until midnight Eastern Time at the end of April 11, 2018. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.

**Electronic Submissions**

Submit electronic comments in the following way:

- Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions.”)

**Written/Paper Submissions**

Submit written/paper submissions as follows:

- Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

**Instructions:** All submissions received must include the Docket No. FDA–2017–N–7007 for “Removal of Certain Time of Inspection and Duties of Inspector Regulations for Biological Products.” Received comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Dockets Management Staff